MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
Cortexyme EPS Ratio 2011-2026 | CRTX
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Cortexyme
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.84 | -1.54 | -3.03 | -2.63 | -1.94 | -3.71 | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.84 | -3.71 | -2.28 |
Quarterly EPS Ratio Cortexyme
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.25 | -0.34 | -0.34 | - | -0.13 | -0.64 | -0.26 | - | -0.15 | -0.14 | -0.34 | - | -0.22 | -0.51 | -0.72 | - | -0.73 | -0.74 | -0.78 | - | -0.73 | -0.6 | -0.61 | - | -0.37 | -0.57 | -1.61 | - | -0.75 | -0.93 | -1.01 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -0.13 | -1.61 | -0.561 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-15.4 | - | 2.43 % | $ 254 M |  Germany |
 |
Aclaris Therapeutics
ACRS
|
-1.71 | $ 3.01 | 3.79 % | $ 233 M |  USA |
 |
AIkido Pharma
AIKI
|
-2.38 | - | 1.93 % | $ 17.4 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-0.53 | $ 3.08 | 0.65 % | $ 7.41 B |  Australia |
 |
Autolus Therapeutics plc
AUTL
|
-0.86 | $ 1.99 | 1.02 % | $ 508 M |  Britain |
 |
AlloVir
ALVR
|
-11.7 | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-10.7 | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-3.25 | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-1.73 | - | - | $ 2.17 B | USA |
 |
Midatech Pharma plc
MTP
|
-31 | - | -18.52 % | $ 27.3 M | Britain |
 |
Biophytis SA
BPTS
|
-0.26 | - | -13.47 % | $ 169 M |  France |
 |
Avenue Therapeutics
ATXI
|
-15.8 | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
0.27 | - | 1083.1 % | $ 745 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-24.9 | - | - | $ 1.01 B | USA |
 |
BioVie
BIVI
|
-12.1 | $ 1.16 | 2.65 % | $ 1.71 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-8.28 | $ 213.24 | 1.87 % | $ 5 B |  Danmark |
 |
BioDelivery Sciences International
BDSI
|
0.85 | - | -4.8 % | $ 255 M | USA |
 |
Athersys
ATHX
|
-0.39 | - | 3.77 % | $ 22.4 M | USA |
 |
ARCA biopharma
ABIO
|
-3.87 | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
-0.79 | - | 4.01 % | $ 150 M |  Canada |
 |
Bellicum Pharmaceuticals
BLCM
|
-0.81 | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-1.42 | - | -7.31 % | $ 87 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-0.09 | - | -15.15 % | $ 60.3 M | Britain |
 |
bluebird bio
BLUE
|
-1.93 | - | - | $ 546 M | USA |
 |
Albireo Pharma
ALBO
|
-1.77 | - | -0.23 % | $ 916 M | USA |
 |
BioNTech SE
BNTX
|
42.2 | $ 95.2 | -0.08 % | $ 27.2 B | Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
-0.01 | $ 0.2 | 8.46 % | $ 435 M |  Israel |
 |
Amphastar Pharmaceuticals
AMPH
|
3.29 | $ 26.78 | -0.81 % | $ 1.3 B | USA |
 |
Catalyst Biosciences
CBIO
|
-1.41 | $ 11.86 | 2.24 % | $ 781 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-0.47 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Anika Therapeutics
ANIK
|
-5.64 | $ 9.61 | 0.63 % | $ 141 M | USA |
 |
Certara
CERT
|
-0.08 | $ 8.81 | -0.56 % | $ 1.41 B | USA |
 |
Celldex Therapeutics
CLDX
|
-2.45 | $ 27.16 | 2.76 % | $ 1.75 M | USA |
 |
Cellectis S.A.
CLLS
|
-2.55 | $ 4.84 | 1.26 % | $ 116 M | France |
 |
Cellectar Biosciences
CLRB
|
-3.5 | $ 2.95 | 7.66 % | $ 36.1 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-10.1 | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
-1.66 | - | 2.71 % | $ 14 M | USA |
 |
Axon Enterprise
AXON
|
4.98 | $ 567.93 | -0.73 % | $ 43 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.46 | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-2.16 | $ 2.6 | 1.96 % | $ 16.3 M | USA |
 |
AstraZeneca PLC
AZN
|
0.08 | $ 91.93 | -0.63 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
-204 | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
-1.06 | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
75.3 | $ 8.92 | -1.0 % | $ 1.46 B | Britain |
 |
ChromaDex Corporation
CDXC
|
0.11 | - | -0.88 % | $ 598 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-13.1 | $ 11.29 | -3.01 % | $ 730 M | USA |